Dark Blue Therapeutics
Graham Craggs is an accomplished professional in the field of biology, currently serving as the Director of Translational and Mechanistic Biology at Dark Blue Therapeutics since February 2023. Previously, Graham held various leadership roles at e-therapeutics PLC, including Head of Therapeutic Discovery and Senior Principal Biologist. Graham's extensive experience at UCB spanned over 16 years, with titles such as Senior Group Leader in Target Evaluation and a Senior Principal Scientist focused on Mechanism of Action. Earlier positions include Senior Scientist roles at OSI Pharmaceuticals and Oxford Glycosciences, as well as a Research Fellow at Yamanouchi Research Institute. Graham obtained a PhD in Oncology from the Paterson Institute for Cancer Research and a BSc in Biochemistry from The University of Manchester.
This person is not in the org chart
This person is not in any teams
Dark Blue Therapeutics
Pioneering the next generation of precision medicines to deliver a portfolio of transformative cancer therapies. Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, UK. We have assembled a highly experienced team, whose expertise spans the breadth of drug development from discovery to approval. This expertise has been gained over many years in the industry and draws from biotech, large pharmaceutical companies and investment management. Dark Blue leverages ground-breaking cancer biology insights, from Oxford University, to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology we match our precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs, delivering medicines that transform the outcomes for cancer patients. We work across a variety of biological mechanisms to identify and pursue only cancer targets that have the highest transformative potential.